Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Benitec Biopharma (BNTC) EBIT Margin (2019 - 2023)

Benitec Biopharma has reported EBIT Margin over the past 5 years, most recently at 65000.0% for Q2 2023.

  • Quarterly results put EBIT Margin at 65000.0% for Q2 2023, changed N/A from a year ago — trailing twelve months through Mar 2024 was 307028.57% (down 27869181.0% YoY), and the annual figure for FY2023 was 25441.33%, down 98380.0%.
  • EBIT Margin reached 65000.0% in Q2 2023 per BNTC's latest filing, down from 8038.89% in the prior quarter.
  • Across five years, EBIT Margin topped out at 8248.57% in Q2 2020 and bottomed at 379300.0% in Q1 2021.
  • Median EBIT Margin over the past 5 years was 8038.89% (2023), compared with a mean of 80620.4%.
  • The largest annual shift saw EBIT Margin tumbled -37176071bps in 2021 before it skyrocketed 37209167bps in 2022.
  • Over 5 years, EBIT Margin stood at 2741.56% in 2019, then plummeted by -11787bps to 325900.0% in 2020, then soared by 94bps to 19340.0% in 2021, then crashed by -107bps to 40071.43% in 2022, then crashed by -62bps to 65000.0% in 2023.
  • Business Quant data shows EBIT Margin for BNTC at 65000.0% in Q2 2023, 8038.89% in Q1 2023, and 40071.43% in Q4 2022.